Related Experiment Video

Updated: Jul 2, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Therapeutic aspects of hepatitis C in hemodialysis patients

Seyed Mohammadmehdi Hosseini Moghaddam1, Seyed Moayed Alavian, Mohammad Rahnavardi

  • 1Urology and Nephrology Research Center (UNRC), Shahid Beheshti University, M.C. (SBUMS), Tehran, Iran.

American Journal of Nephrology
|August 23, 2008
PubMed

Insights

Treating hepatitis C in hemodialysis patients is challenging. Pegylated interferon (PEG-IFN) shows promise, but ribavirin use in renal failure patients requires caution.

Area of Science:

  • Hepatology
  • Nephrology
  • Pharmacology

Background:

  • Hepatitis C treatment in hemodialysis (HD) patients presents significant challenges due to co-existing clinical issues and drug side effects.
  • Conventional therapies often have limited efficacy or adverse event profiles in this vulnerable population.

Purpose of the Study:

  • To review the efficacy and safety of interferon-based therapies for hepatitis C in patients undergoing hemodialysis.
  • To evaluate the suitability of newer treatment modalities in this specific patient group.

Main Methods:

  • A comprehensive literature search was conducted in MEDLINE and EMBASE databases up to May 2007.
  • Studies published after 1995 were included, and eligible manuscripts were independently reviewed by two researchers.
  • Focus on identifying therapeutic options suitable for patients with renal failure.

Main Results:

  • Interferon-alpha (IFN-alpha) has been a traditional treatment, but pegylated interferon (PEG-IFN) demonstrates improved outcomes in HD patients.
  • While ribavirin is effective in non-renal patients, its use in renal failure is associated with severe complications.
  • Both conventional IFN and PEG-IFN appear beneficial for managing hepatitis C in HD patients.

Conclusions:

  • Conventional IFN and PEG-IFN are viable options for hepatitis C management in hemodialysis patients.
  • Further research into novel therapeutic agents is necessary to optimize treatment strategies for this population.
Abstract

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...